ScholarIQanswers from OpenAlex & ORCID
Michelle A. Fanale
ResearcherPublications, citations & collaboration network
Michelle A. Fanale is a researcher indexed in ScholarIQ from OpenAlex & ORCID.
How many works does Michelle A. Fanale have?
ScholarIQindexed works
Michelle A. Fanale has 471 works in the ScholarIQ index. The count is the OpenAlex total, not the number of papers listed on this page.
How many citations does Michelle A. Fanale have?
ScholarIQcitation count
Michelle A. Fanale has 16,802 citations in the OpenAlex counts ScholarIQ stores.
What is the h-index of Michelle A. Fanale?
ScholarIQh-index
Michelle A. Fanale has an h-index of 54 in OpenAlex.
What is the i10-index of Michelle A. Fanale?
ScholarIQi10-index
Michelle A. Fanale has an i10-index of 182 in OpenAlex.
What is the ORCID of Michelle A. Fanale?
ScholarIQorcid
The ORCID for Michelle A. Fanale is on the source record.
What is the OpenAlex record for Michelle A. Fanale?
ScholarIQopenalex
The OpenAlex for Michelle A. Fanale is on the source record.
What are the most-cited papers on Michelle A. Fanale?
ScholarIQmost cited works
Brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma (ECHELON-2): a global, double-blind, randomised, phase 3 trial
Steven M. Horwitz, Owen A. O’Connor, Barbara Pro, Tim Illidge, Michelle A. Fanale, Ranjana H. Advani, Nancy L. Bartlett, Jacob Haaber Christensen, Franck Morschhauser, Eva Domingo‐Doménech, Giuseppe Rossi, Won Seog Kim, Tatyana Feldman, Anne Lennard, David Belada, Árpád Illés, Kensei Tobinai, Kunihiro Tsukasaki, Su‐Peng Yeh, Andrei R. Shustov, Andreas Hüttmann, Kerry J. Savage, Sam Yuen, Swaminathan P. Iyer, Pier Luigi Zinzani, Zhaowei Hua, Meredith Little, Shangbang Rao, Joseph Woolery, Thomas Manley, Lorenz Trümper, David M. Aboulafia, Ranjana H. Advani, Önder Alpdoğan, Kiyoshi Ando, Luca Arcaini, Luca Baldini, Naresh Bellam, Nancy L. Bartlett, David Belada, Dina Ben Yehuda, Fabio Benedetti, Peter Borchman, Dominique Bordessoule, Pauline Brice, Javier Briones, Dolores Caballero, Angelo Michele Carella, Hung Chang, June Weon Cheong, Seok‐Goo Cho, Ilseung Choi, Sylvain Choquet, Andrei Coliţă, Angela Giovanna Congui, Francesco d’Amore, Nam H. Dang, Kelly Davison, Sophie de Guibert, Peter de Nully Brown, Vincent Delwail, Judit Demeter, Francesco Di Raimondo, Young Rok, Eva Domingo, Michael G. Douvas, Martin Dreyling, Thomas Ernst, Michelle A. Fanale, Keith Fay, Tatyana Feldman, Silvia Ferrero, Ian W. Flinn, Andres Forero‐Torres, Christopher P. Fox, Jonathan W. Friedberg, Noriko Fukuhara, José A. García‐Marco, Jorge Gayoso Cruz, José Codina, Rémy Gressin, Andrew Grigg, Ronit Gurion, Jacob Haaber Christensen, Corinne Haïoun, Roman Hájek, Mathias Hänel, Kiyohiko Hatake, Robert Hensen, Netanel A. Horowitz, Steven M. Horwitz, Andreas Hüttmann, Árpád Illés, Tim Illidge, Kenichi Ishizawa, Miguel Islas‐Ohlmayer, Eric D. Jacobsen, Murali Janakiram, Wojciech Jurczak, Mark Kaminski
Lenalidomide in combination with rituximab for patients with relapsed or refractory mantle-cell lymphoma: a phase 1/2 clinical trial
Michael Wang, Luis Fayad, Nicolaus A. Wagner‐Bartak, Liang Zhang, Fredrick Hagemeister, Sattva S. Neelapu, Felipe Samaniego, Peter McLaughlin, Michelle A. Fanale, Anas Younes, Fernando Cabanillas, Nathan Fowler, Kate J. Newberry, Luhong Sun, Ken H. Young, Richard E. Champlin, Larry W. Kwak, Lei Feng, Maria Badillo, Maria Teresa Bejarano, Kimberly Hartig, Wendy Chen, Yi‐Ming Chen, Catriona Byrne, Neda Bell, Jerome B. Zeldis, Jorge Romaguera